6.
Schmidt J
. Current Classification and Management of Inflammatory Myopathies. J Neuromuscul Dis. 2018; 5(2):109-129.
PMC: 6004913.
DOI: 10.3233/JND-180308.
View
7.
De Bleecker J, Amato A, Aronica E, Benveniste O, de Bleecker J, de Boer O
. 205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands. Neuromuscul Disord. 2015; 25(3):268-72.
DOI: 10.1016/j.nmd.2014.12.001.
View
8.
Uruha A, Noguchi S, Sato W, Nishimura H, Mitsuhashi S, Yamamura T
. Plasma IP-10 level distinguishes inflammatory myopathy. Neurology. 2015; 85(3):293-4.
DOI: 10.1212/WNL.0000000000001767.
View
9.
Reed A, Crowson C, Dvergsten J
. A Path to Prediction of Outcomes in Juvenile Idiopathic Inflammatory Myopathy. Front Immunol. 2019; 10:638.
PMC: 6454149.
DOI: 10.3389/fimmu.2019.00638.
View
10.
Tanboon J, Inoue M, Saito Y, Tachimori H, Hayashi S, Noguchi S
. Dermatomyositis: Muscle Pathology According to Antibody Subtypes. Neurology. 2021; 98(7):e739-e749.
PMC: 8865893.
DOI: 10.1212/WNL.0000000000013176.
View
11.
Kubota A, Shimizu J, Unuma A, Maeda M, Shirota Y, Kadoya M
. Alanine transaminase is predominantly increased in the active phase of anti-HMGCR myopathy. Neuromuscul Disord. 2021; 32(1):25-32.
DOI: 10.1016/j.nmd.2021.10.007.
View
12.
Bohlmeyer T, Wu A, Perryman M
. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Rheum Dis Clin North Am. 1994; 20(4):845-56.
View
13.
Allenbach Y, Benveniste O, Stenzel W, Boyer O
. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020; 16(12):689-701.
DOI: 10.1038/s41584-020-00515-9.
View
14.
Caproni M, Cardinali C, Parodi A, Giomi B, Papini M, Vaccaro M
. Amyopathic dermatomyositis: a review by the Italian Group of Immunodermatology. Arch Dermatol. 2002; 138(1):23-7.
DOI: 10.1001/archderm.138.1.23.
View
15.
Pluk H, van Hoeve B, van Dooren S, Stammen-Vogelzangs J, van der Heijden A, Schelhaas H
. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013; 73(3):397-407.
DOI: 10.1002/ana.23822.
View
16.
Chen M, Quan C, Diao L, Xue F, Xue K, Wang B
. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis. Br J Dermatol. 2018; 179(6):1334-1341.
DOI: 10.1111/bjd.17079.
View
17.
Zhou J, Zhao L, Xiao Y, Xie S, Long Y, Wei Y
. The Expression of Cytokine Profiles and Related Receptors in Idiopathic Inflammatory Myopathies. Front Pharmacol. 2022; 13:852055.
PMC: 9065407.
DOI: 10.3389/fphar.2022.852055.
View
18.
van der Meulen M, Bronner I, Hoogendijk J, Burger H, van Venrooij W, Voskuyl A
. Polymyositis: an overdiagnosed entity. Neurology. 2003; 61(3):316-21.
DOI: 10.1212/wnl.61.3.316.
View
19.
Amlani A, Choi M, Tarnopolsky M, Brady L, Clarke A, Torre I
. Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis. Front Immunol. 2019; 10:745.
PMC: 6465553.
DOI: 10.3389/fimmu.2019.00745.
View
20.
Larman H, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H
. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013; 73(3):408-18.
DOI: 10.1002/ana.23840.
View